What do patients really think of oral steroids for asthma attacks? A discrete choice experiment (ID 526)
Nuffield Department of Medicine, University of Oxford
Funding: NIHR Biomedical Research Centre grant.
Abstract
IntroductionOral corticosteroids (OCS) are guideline treatment for all asthma attacks based on trials showing reduced relapse and hospitalisation rates and faster symptom resolution. These trials may overestimate treatment effect of mild attacks as they pre-date widespread inhaled corticosteroid use. Cumulative OCS exposure is associated with side effects including diabetes, osteoporosis, and cardiovascular disease.
Aims
To define patients’ and healthcare professionals’ (HCPs) preferences for clinical outcomes and side effects of OCS treatment for asthma attacks.
Methods
A discrete choice experiment (DCE) on patients and HCPs in the UK and New Zealand. Participants chose from 12 hypothetical pairs comprising OCS treatment benefits and risks. The DCE design was informed by the clinical literature, a focus group, and pilot testing. Choice models analysed preferences of the sample.
Results
824 patients and 171 HCPs completed the DCE. The strongest preference of patients and HCPs was to avoid side effects of OCS. (Figure 1). Patients with poorly controlled asthma accepted more side effects in exchange for less relapse.
Conclusions
Patients and HCPs strongly value treatment of asthma attacks that avoids OCS side effects. In return, they are willing to trade-off substantial treatment benefits. Our data supports the concept of biomarker-directed trials of asthma attack treatment to minimise OCS exposure.
European Respiratory Society Congress 2024
Conflicts of interest: None
The conference has been instigated and organised by PCRS. We are grateful to sponsors and exhibitors who have contributed funding towards this event in return for exhibition space. Neither sponsors or exhibitors have had any input into the agenda or the selection of speakers with the exception of any sponsored satellite symposia which are clearly indicated. View the full list of sponsors.